



Media Release

IMMEDIATE RELEASE

Media Contact

Ian Stone

Russo Partners

Tel: +1 619 528 2220

ian.stone@russopartnersllc.com

Amira Pharmaceuticals to Present at the BIOCOM Investor Conference in San Diego

SAN DIEGO, Oct. 22, 2009 – Amira Pharmaceuticals, Inc., a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease, announced today that Robert Baltera, Chief Executive Officer, will present at the 4th Annual BIOCOM Investor Conference. The presentation is scheduled for 11 a.m. PDT on Tuesday, October 27, at the Hyatt Regency La Jolla in San Diego, Calif. The BIOCOM Investor Conference includes presentations from top companies from throughout the Southwest.

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease. Our discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and fibrotic diseases. Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease.

Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions. Its scientific founders have successfully worked together for more than a decade and were pivotal in the discovery of a number of inflammatory drugs, including Singulair®. The drug hunters at Amira are now actively leveraging their history of success to create high-value compounds for the future. For more information, visit www.amirapharm.com.